Silo Pharma Inc Asset Resilience Ratio
Silo Pharma Inc asset resilience ratio. Silo Pharma Inc (SILO) has an Asset Resilience Ratio of 36.22% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Silo Pharma Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Silo Pharma Inc (2017–2025)
Asset resilience ratio of Silo Pharma Inc from 2017 to 2025. This chart shows how Silo Pharma Inc's Asset Resilience Ratio has changed over time. Read Silo Pharma Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Silo Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SILO total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.16 Million | 36.22% |
| Total Liquid Assets | $2.16 Million | 36.22% |
Asset Resilience Insights
- Very High Liquidity: Silo Pharma Inc maintains exceptional liquid asset reserves at 36.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Silo Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Silo Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Silo Pharma Inc Asset Resilience Ratio by Year (2017–2025)
Silo Pharma Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Silo Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.75% | $2.11 Million | $7.61 Million | -15.09pp |
| 2024-12-31 | 42.83% | $3.17 Million | $7.41 Million | -10.62pp |
| 2023-12-31 | 53.46% | $4.14 Million | $7.75 Million | +53.43pp |
| 2022-12-31 | 0.03% | $3.12K | $11.64 Million | -3.98pp |
| 2021-12-31 | 4.00% | $420.00K | $10.49 Million | +3.99pp |
| 2020-12-31 | 0.01% | $200.00 | $1.43 Million | -80.42pp |
| 2017-12-31 | 80.43% | $1.32 Million | $1.64 Million | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more